SPOTLIGHT: Boehringer launch aided by charity

Boehringer Ingelheim launched its blood thinner Pradaxa last week, getting a media boost from the backing of Lifeblood, a charity that's been lobbying for changes to the National Institute for Clinical Excellence's thrombosis treatment guidelines. Release | Report

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.